ATNM · Actinium Pharmaceuticals, Inc.
$0.86
-0.03 (-2.94%)
At close · Jul 24
Market Cap
$26.98M
Shares
31.37M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$90K
FY2025
Net Income
-$33.89M
+11.4%
FY2025
Operating Margin
-40274.44%
FY2025
Diluted EPS
-$1.09
+14.2%
FY2025
Operating Cash Flow
-$24.58M
+25.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 | FY2002 | FY2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $90K | — | $81K | $1.03M | $1.14M | — | — | — | — | — | — | — | — | — | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| $3.48M | — | — | $3.1M | $1.09M | $190K | $178K | $172K | $173.36K | $5430 | -$5007 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $900K | — | — | — | — | — | — | — | — | — | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| $17.63M | $21.12M | $30.05M | $38.67M | $23.14M | $18.03M | $16.09M | $16.55M | $17.09M | $17.72M | $17.83M | $13.5M | $12.27M | $3.11M | $3.44M | $323.79K | — | — | — | — | — | — | — | — | — | — | |
| $7.98M | $15.21M | $12.08M | $13.33M | $12M | $8.08M | $6.31M | $5.52M | $6.73M | $9.19M | $9.02M | $11.27M | $10.18M | $3.48M | $4.51M | $2.96M | — | — | — | — | — | — | — | — | — | — | |
| — | $173K | $197K | $207K | $699K | $524K | $447K | $420K | $50.72K | — | $77.52K | $53.47K | $37.91K | $1560 | $581 | $633 | — | — | — | — | — | — | — | — | — | — | |
| $25.6M | $36.34M | $42.12M | $52M | $35.13M | $26.11M | $22.39M | $22.07M | $23.83M | $26.91M | $26.85M | $24.83M | $22.48M | $6.59M | $7.95M | $3.28M | $26.05K | — | — | — | — | — | — | — | — | — | |
| -$25.51M | -$36.25M | -$42.12M | -$51.92M | -$34.1M | -$24.96M | -$22.39M | -$22.07M | -$23.83M | -$26.91M | -$26.85M | -$24.83M | -$22.48M | -$6.59M | -$7.95M | -$3.28M | -$26.05K | — | — | — | — | — | — | — | — | — | |
| — | -40274.44% | — | -64098.77% | -3311.07% | -2182.17% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$36.07M | -$41.92M | -$51.71M | -$33.41M | -$24.44M | -$21.95M | -$21.65M | -$23.78M | — | -$26.77M | -$24.78M | -$22.44M | -$6.59M | -$7.95M | -$3.28M | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $5007 | $7868 | $866 | $2508 | $1.1M | -$175.09K | -$6439 | — | — | — | — | — | — | — | — | — | |
| $2.04M | $2.36M | $3.88M | $3.1M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $2.04M | $2.36M | $3.88M | $3.1M | $1.09M | $190K | $178K | $172K | $173.36K | $309.55K | $2.53M | $3.8M | -$2.21M | -$4.18M | -$413.91K | $161.13K | $27.73K | — | — | — | — | — | — | — | — | — | |
| $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | -$834 | — | — | — | — | — | — | — | — | — | |
| -$23.47M | -$33.89M | -$38.24M | -$48.82M | -$33.02M | -$24.77M | -$22.22M | -$21.9M | -$23.65M | -$26.6M | -$24.32M | -$21.03M | -$24.69M | -$10.77M | -$8.36M | -$3.44M | -$467.27K | -$3.43M | -$5.57M | -$5.62M | -$6.05M | -$4.58M | -$5.73M | -$3.53M | -$3.19M | -$5.09M | |
| — | -37652.22% | — | -60269.14% | -3205.53% | -2165.56% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | -$24.77M | -$22.22M | -$21.9M | -$23.65M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$33.91M | -$38.24M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$1.09 | -$1.27 | -$1.83 | -$1.37 | -$1.20 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$1.09 | -$1.27 | -$1.83 | -$1.37 | -$1.20 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 31.2M | 30.07M | 26.6M | 24.14M | 20.57M | 12.13M | 4.98M | 3.53M | 2.22M | 1.62M | 1.27M | 912.12K | 758.43K | 36.78K | 26.73K | — | — | — | — | — | — | — | — | — | — |
| shares | — | 31.2M | 30.07M | 26.6M | 24.14M | 20.57M | 12.13M | 4.98M | 3.53M | 2.22M | 1.62M | 1.27M | 912.12K | 758.43K | 36.78K | 26.73K | — | — | — | — | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Other Revenue | $90,000 | — | $81,000 | $1,030,000 |
| Grant Revenue | — | $100,000 | — | — |